Overview

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

Status:
Completed
Trial end date:
2018-12-11
Target enrollment:
Participant gender:
Summary
A Phase 2 study of Bermekimab (MABp1) in patients with atopic dermatitis.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC
XBiotech, Inc.
Treatments:
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins